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The coactivator PGC-1α is a key regulator of mitochondrial biogenesis and respiration, 
mediating expression of several transcription factors required for these programs. Three 
new studies reveal that PGC-1α expression is downregulated in patients with Huntington’s 
disease (HD) and in several animal models of this neurodegenerative disorder, implicating 
PGC-1α in HD pathogenesis and providing a connection between impaired energy metabo-
lism and neurodegeneration (Cui et al., 2006; Weydt et al., 2006; St-Pierre et al., 2006).Since its discovery a decade ago, PGC-1α (peroxi-
some proliferator-activated receptor-γ coactivator 1α) 
(Puigserver et al., 1998) has been implicated in energy 
homeostasis, adaptive thermogenesis, β-oxidation of 
fatty acids, and glucose metabolism (for review see 
Puigserver and Spiegelman, 2003). Originally identified 
as a PPAR-γ-interacting protein in brown adipose tis-
sue, PGC-1α and its close homolog, PGC-1β, are highly 
expressed in tissues with increased energy demands 
and large numbers of mitochondria, including brown 
adipose tissue, heart muscle, and slow-twitch skeletal 
muscle (Puigserver et al., 1998). PGC-1α’s ability to 
activate a diverse set of metabolic programs in differ-
ent tissues depends on its ability to form heteromeric 
complexes with a variety of transcription factors includ-
ing NRF-1 and NRF-2 and the nuclear hormone recep-
tors PPARα, PPARδ, ERRα, and TR (for review see Lin et 
al., 2005). Of particular interest are NRF-1, NRF-2, and 
ERRα, given that they regulate the expression of many 
nuclear-encoded mitochondrial genes including those 
encoding cytochrome c, complexes I–V, and mitochon-
drial transcription factor A (Tfam) (for review see Kelly 
and Scarpulla, 2004). Three new studies—two in Cell 
(Cui et al., 2006; St-Pierre et al., 2006) and one in Cell 
Metabolism (Weydt et al., 2006)—now implicate loss 
of PGC-1α function in the neurodegenerative disorder 
Huntington’s disease (HD).
HD is an autosomal-dominant disorder character-
ized by lesions in the striatum of the brain that cause 
progressive behavioral and cognitive impairments and 
involuntary choreiform movements. The genetic defect 
is caused by expansion of an unstable CAG repeat in 
the huntingtin gene resulting in a greatly expanded poly-
glutamine tract in the protein it encodes. How the mutant 
huntingtin protein elicits its toxic effects is unclear, but 
several mechanisms have been postulated including 
transcriptional dysregulation, abnormalities in energy 
metabolism, and oxidative damage (reviewed in Browne 
and Beal, 2004).One of the first indications that bioenergetic defects 
might be implicated in HD pathogenesis came from the 
finding that HD patients display pronounced weight loss, 
despite increased caloric intake. Imaging with positron 
emission tomography (PET) and nuclear magnetic reso-
nance (NMR) spectroscopy revealed a marked reduction 
in glucose metabolism and an increase in lactate, respec-
tively, in the basal ganglia of HD patients. In addition, 
biochemical studies revealed reduced activity of several 
key components of oxidative phosphorylation, including 
complexes II, III, and IV of the electron transport chain 
in mitochondria of striatal neurons in HD patients at an 
advanced stage of disease (reviewed in Browne and 
Beal, 2004). Studies on lymphoblasts from HD patients 
revealed other mitochondrial abnormalities including a 
decreased membrane resting potential, impaired cal-
cium ion homeostasis (Panov et al., 2002), and marked 
morphological abnormalities including derangement 
of the mitochondrial matrix and cristae (Squitieri et al., 
2006). This appears to be a direct effect of mutant hunt-
ingtin, given that these mitochondrial abnormalities can 
be recapitulated in normal lymphoblasts treated with a 
fusion protein composed of a peptide containing a path-
ogenic polyglutamine tract (Panov et al., 2002). Indeed, 
there is evidence from an HD mouse model (YAC72) and 
from cultured HD striatal neurons expressing endog-
enous mutant huntingtin (STHdhQ111) that this mutant 
protein associates directly with the outer mitochondrial 
membrane (Choo et al., 2004). The STHdhQ111 cultured 
cell line also displayed reduced rates of oxygen con-
sumption and ATP production (Milakovic and Johnson, 
2005) and increased sensitivity to 3-nitropropionic acid 
(3-NP) (Gines et al., 2003), a complex II inhibitor capable 
of inducing HD-like symptoms in many different species. 
The molecular basis of these mitochondrial defects in 
HD remains unclear. It has been proposed that aberrant 
transcriptional regulation of nuclear-encoded mitochon-
drial genes may be involved in HD pathogenesis. Indeed, 
mutant huntingtin binds to several key transcription fac-Cell 127, November 3, 2006 ©2006 Elsevier Inc. 465
Figure 1. Mechanisms by which Mutant Huntingtin Impairs PGC-1α Function in HD Pathogenesis
(Top) In Huntington’s disease (HD), Weydt et al. (2006) show that the mutant huntingtin (mHtt) protein impairs the ability of PGC-1α to switch on 
downstream target genes such as the gene encoding UCP-1 in brown adipose tissue. Although there is no direct evidence that mHtt binds directly 
to PGC-1α, mHtt does block PGC-1α’s function as a coactivator. (Bottom) Cui et al. (2006) show that association of mHtt with the CREB/TAF4 com-
plex on the PGC-1α promoter impairs PGC-1α activity by blocking transcription of its gene. These two models for how mHtt may regulate PGC-1α 
activity are not mutually exclusive because mHtt could have different modes of action depending on the tissue. Impairment of PGC-1α function 
and downregulation of its mitochondrial target genes could lead to abnormalities in mitochondrial function and energy metabolism, contributing to 
neurodegeneration in susceptible neurons (Cui et al., 2006; Weydt et al., 2006). Meanwhile impaired PGC-1α transcription and activity impact the 
enzyme system that combats reactive oxygen species (ROS). This leads to downregulation of ROS defense genes encoding, for example, SOD1, 
SOD2, and glutathione peroxidase (GPx1), resulting in increased oxidative damage and neuronal death (St-Pierre et al., 2006).tors—including Sp1, TAFII130, and CREB binding protein 
(reviewed in Sugars and Rubinsztein, 2003)—and down-
regulates their activity. The three new studies in Cell and 
Cell Metabolism tie together these disparate strands of 
information, implicating mutant huntingtin in the dys-
regulation of PGC-1α transcription and activity, impaired 
mitochondrial function, and HD pathogenesis (Cui et al., 
2006; St-Pierre et al., 2006; Weydt et al., 2006).
Initial interest that PGC-1α might play a role in HD 
pathogenesis came from studies on mice lacking PGC-
1α (Lin et al., 2004; Leone et al., 2005). These mice 
display a profound spongiform pattern of lesions in the 
central nervous system, predominantly in the striatum, 
and exhibit abnormalities in brown adipose tissue. In 
addition, mice lacking PGC-1α display impaired ther-
moregulation, marked hyperactivity, and frequent limb 
clasping. Neurodegeneration predominantly in the stria-
tum together with hyperactivity are features reminiscent 
of HD in humans, potentially implicating PGC-1α in the 
selective vulnerability of striatal neurons in HD. But what 
is the mechanism underpinning this selective vulnerabil-
ity? One possibility is increased oxidative stress.
In their new study in Cell, St-Pierre et al. (2006) provide 
evidence that PGC-1α is a potent suppressor of reac-
tive oxygen species (ROS) and induces production of 
ROS scavenging enzymes. They show that in response 
to treatment with the oxidative stressor, hydrogen per-
oxide, there is a ?6-fold increase in PGC-1α expres-
sion levels (and those of the related factor, PGC-1β) in 
a mouse embryonic fibroblast cell line. Concomitantly, 
there is increased expression of genes encoding ROS 
defense enzymes, including copper/zinc superoxide dis-466 Cell 127, November 3, 2006 ©2006 Elsevier Inc.mutase (SOD1), manganese SOD (SOD2), catalase, and 
glutathione peroxidase. To definitively determine the role 
of PGC-1α in the regulation of ROS defense enzymes, 
the authors infected the mouse embryonic fibroblast 
cell line with an adenovirus encoding a small inhibitory 
RNA (RNAi) against PGC-1α. When these RNAi-treated 
cells were exposed to hydrogen peroxide, they exhibited 
reduced expression of genes encoding PGC-1α and the 
ROS defense system (including SOD1, SOD2, and glu-
tathione peroxidase). Analysis of mice lacking PGC-1α 
revealed that the basal expression of SOD1, SOD2, and 
catalase is considerably lower in the heart and brain, 
regions known to be very sensitive to oxidative stress. 
St-Pierre et al. (2006) also provide evidence that the 
master transcription factor CREB is important in the 
regulation of PGC-1α activity in response to hydrogen 
peroxide treatment. CREB is known to be an important 
regulator of PGC-1α expression under normal physi-
ological conditions (Herzig et al., 2001; Handschin et al., 
2003). St-Pierre et al. (2006) now show that PGC-1α-
deficient mice are more sensitive to the effects of two 
neurotoxins—MPTP, a complex I inhibitor that targets the 
substantia nigra, and kainic acid, a glutamate receptor 
agonist that induces excitotoxicity in the hippocampus—
exhibiting increased apoptosis of neurons and oxidative 
damage in the brain. As the authors point out, however, 
it is not yet possible to conclude that a lack of PGC-1α 
is the cause of the more pronounced neurodegenera-
tion in the knockout mice compared to control animals 
treated with the two neurotoxins. However, it does seem 
likely that loss of PGC-1α enhances neurodegeneration 
in response to these neurotoxins, particularly given that 
MPTP, which induces parkinsonian symptoms in mice 
and nonhuman primates, is known to cause oxidative 
damage and mitochondrial dysfunction.
In their new work, Cui et al. (2006) and Weydt et al. 
(2006) address separately the specific role of PGC-1α 
in mitochondrial dysfunction and HD pathogenesis. Cui 
et al. (2006) use three different sources of striatal neu-
rons for their experiments: striata from postmortem HD 
patient brains, striata from an HD knockin mouse model 
that overexpresses mutant huntingtin, and the STHdhQ111 
cultured HD striatal cell line. The authors report a marked 
reduction in the expression of PGC-1α mRNA in these 
three sources of striatal neurons and suggest that mutant 
huntingtin interferes with formation of the CREB/TAF4 
complex that regulates transcription of the gene encod-
ing PGC-1α (see Figure 1). In addition, the STHdhQ111 stri-
atal neuronal line exhibited reduced expression of known 
mitochondrial gene targets of PGC-1α, including cyto-
chrome c and cytochrome oxidase IV. Of particular inter-
est, in knockin HD mice (with 140 CAG repeats inserted 
into the murine huntingtin gene), the expression of PGC-
1α was reduced several-fold in medium spiny neurons but 
increased almost 50-fold in nNOS interneurons. This sug-
gests that the selective vulnerability of medium spiny neu-
rons and the resistance of interneurons (which are spared 
in HD) may be a consequence of altered PGC-1α expres-
sion. An important question is whether overexpression of 
PGC-1α is neuroprotective? A lentiviral vector expressing 
PGC-1α administered directly to the striatum of the R6/2 
HD mouse model (in which about 150 CAG repeats are 
expressed in an N-terminal fragment of the mutant hunt-
ingtin gene) induced a marked increase in mean neuronal 
volume. This indicates that PGC-1α overexpression may 
prevent neuronal atrophy in these animals. A key question, 
which Cui et al. (2006) do not address, is whether overex-
pression of PGC-1α results in improved survival or motor 
performance in the R6/2 HD mice. Future experiments 
are needed to confirm whether PGC-1α is neuroprotec-
tive. However, the authors do show that downregulation 
of PGC-1α worsens behavioral and neuropathological 
abnormalities in a PGC-1α knockout/HD knockin mouse 
model (PGC-1α KO/KI). The knockin HD mouse has a 
relatively mild phenotype (Menalled et al., 2003), whereas 
the PGC-1α KO/KI animals display marked worsening of 
motor performance and reductions in striatal neuronal 
volume at 6 months of age compared to their PGC-1α 
knockout or HD knockin littermates. Moreover, these KO/
KI mice are more susceptible to the neurotoxic effects of 
3-NP, which is not surprising given that oxidative stress is 
important in 3-NP-mediated neurotoxicity and that PGC-
1α regulates the production of antioxidant enzymes. Cui 
et al. (2006) further show that mutant huntingtin interferes 
with the ability of CREB/TAF4 to bind to the PGC-1α pro-
moter and to induce transcription of the PGC-1α gene 
(see Figure 1).
In a related study, Weydt et al. (2006) provide further 
evidence of impaired PGC-1α function in HD. Using 
microarray expression data from the caudate nucleus of HD patient postmortem brain tissue, the authors 
report reduced expression of 24 out of 26 PGC-1α tar-
get genes. Similar to the Cui et al. (2006) findings, Weydt 
et al. (2006) report reduced PGC-1α mRNA expression 
in the striatum of N171-82Q HD mice. Collectively, these 
data support a role for interference with PGC-1α tran-
scription in the striatal neurodegeneration characteristic 
of HD.
Expression of PGC-1α is rapidly induced in response 
to cold, and this coactivator regulates expression of 
key components of adaptive thermogenesis including 
UCP-1, which uncouples respiration resulting in heat 
production in brown adipose tissue. Weydt et al. (2006) 
report marked hypothermia at baseline temperatures 
and following cold exposure in both the N171-82Q and 
R6/2 HD mouse models. Following cold exposure, 
UCP-1 expression is decreased in brown adipose tis-
sue from N171-82Q HD mice relative to wild-type ani-
mals, implicating impaired PGC-1α function in these 
mice. Failure to induce expression of the UCP-1 gene 
and other PGC-1α target genes is further demonstrated 
in pre-adipocyte cells and in primary brown adipocytes 
from N171-82Q mice. In these animals, there is evi-
dence for a reduced ATP/ADP ratio and reduced num-
bers of mitochondria in their adipocytes, as well as 
abnormal brown adipose tissue, similar to the findings 
in PGC-1α-deficient mice (Lin et al., 2004). The finding 
that UCP-1 expression but not PGC-1α expression is 
reduced suggests an alternative way in which mutant 
huntingtin could affect the function of PGC-1α. Cui et 
al. (2006) propose that mutant huntingtin may inter-
fere with the transcription of PGC-1α, whereas Weydt 
et al. (2006) suggest that mutant huntingtin may bind 
to PGC-1α, impairing its ability to upregulate expres-
sion of its downstream target genes including UCP-1 in 
brown adipose tissue (see Figure 1).
The three new studies implicate PGC-1α as an impor-
tant mediator in protecting neurons against oxidative 
damage, and its loss of function may contribute to HD 
pathogenesis. However, to definitively demonstrate 
that PGC-1α is involved in HD pathogenesis will require 
crossing a mouse overexpressing a brain-specific form 
of PGC-1α with an HD mouse strain. The resulting off-
spring should provide important information on both the 
functional and neuroprotective effects of PGC-1α in HD 
pathogenesis. The finding that PGC-1α expression is 
impaired in the striatum of HD patients raises the pos-
sibility that molecules that activate PGC-1α may be thera-
peutically useful. Such molecules are already in devel-
opment because reduced PGC-1α expression has been 
strongly implicated in obesity and type II diabetes, which 
are major health problems (Puigserver and Spiegelman, 
2003). These therapeutic agents may be valuable for 
treating HD as well as other neurodegenerative diseases 
in which mitochondrial dysfunction and oxidative damage 
play an important pathogenic role, such as Alzheimer’s 
disease, Parkinson’s disease, and Amyotrophic Lateral 
Sclerosis (reviewed in Lin and Beal, 2006).Cell 127, November 3, 2006 ©2006 Elsevier Inc. 467
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